Persbericht
8 maart 2019
07u00 CET

Celyad benoemt Anne Moore tot Vice President Corporate Strategy

Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussel en Parijs, en NASDAQ: CYAD), een klinisch biofarmaceutisch bedrijf dat zich richt op de ontwikkeling van celgebaseerde CAR-T behandelingen, kondigde vandaag de benoeming aan van Anne Moore, PhD, tot Vice President Corporate Strategy. Dr. Moore zal verantwoordelijk zijn voor het leiden van de bedrijfsstrategie inclusief communicatie en zal een belangrijk lid zijn van het business development team. Dr. Moore zal gevestigd zijn in Mont-Saint-Guibert, België en zal rapporteren aan Filippo Petti, Chief Financial Officer.

"We zijn erg blij Anne te mogen verwelkomen in ons team", aldus de heer Petti. "Haar wetenschappelijke en financiële achtergrond, gekoppeld aan haar brede ervaring in de industrie, zal een waardevol strategisch inzicht bieden om Celyad's toekomstige succes en groei te begeleiden ."

"Ik ben vereerd en enthousiast om me aan te sluiten bij Celyad in zo'n transformerende tijd," zei Dr. Moore. "De autologe en allogene CAR-T celtherapiebenaderingen van het bedrijf hebben baanbrekend potentieel. Bovendien zou het shRNA-platform van het bedrijf moeten helpen om de persistentie van dergelijke therapieën verder te verfijnen en te verhogen. Met zoveel krachtige hulpmiddelen bij de hand zie ik een groot potentieel voor het bedrijf om therapieën te ontwikkelen ten voordele van patiënten. Ik ben erop gebrand om snel aan de slag te gaan met het doorgewinterde leiderschapsteam van Celyad om onze toekomstige strategie aan te sturen".

Dr. Moore brengt meer dan 12 jaar wereldwijde ervaring in strategy consulting en investment banking mee naar Celyad. Voordat ze bij Celyad kwam werken, was Dr. Moore vicepresident van investment banking in de gezondheidszorg bij Bryan, Garnier & Co., waar ze leiding gaf aan talrijke aandelenfinanciering en strategische engagementen voor klanten in heel Europa en de Verenigde Staten. Ze heeft ook acht jaar in New York gewerkt met organisaties als Credit Suisse, Huron Consulting Group en Bionest Partners, waar ze middelgrote biotech tot grotere farmaceutische bedrijven adviseerde over productlanceringen, marketing, patiëntendiensten, messaging en branding. Daarvoor werkte ze in management consulting in Parijs, waar ze startende bedrijven hielp bij het vormgeven van groeistrategieën en het overbrengen van hun boodschap.

Anne heeft een PhD in Humane Genetica en Fysiologie van de Universiteit van Parijs XII en een Advanced Masters in Biotechnology Management van de Toulouse Business School.

EINDE

About Celyad

Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based therapies. Celyad utilizes its expertise in cell engineering to target cancer. Celyad's CAR-T cell platform has the potential to treat a broad range of solid and hematologic tumors. Its lead oncology candidate, CYAD-01 (CAR-T NKG2D), is currently being evaluated in a Phase I dose escalation clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers including five solid tumors (colorectal, ovarian, bladder, triple-negative breast and pancreatic cancers) and two hematological tumors (acute myeloid leukemia and multiple myeloma). The safety and clinical activity of the CYAD-01 therapy concurrently administered with standard-of-care treatments or preconditioning chemotherapy is also being assessed in a full clinical development program focused on acute myeloid leukemia and colorectal cancer. Celyad was founded in 2007 and is based in Mont-Saint-Guibert, Belgium, and New York, NY. Celyad's ordinary shares are listed on the Euronext Brussels and Euronext Paris exchanges, and its American Depository Shares are listed on the Nasdaq Global Market, all under the ticker symbol CYAD.

For more information, please contact:

Celyad
Filippo Petti, Chief Financial Officer – investors@celyad.com
Anne Moore, Vice President Corporate Srategy - T: +32(0) 10 39 41 87 **- Communications@celyad.com**

For Belgium: Comfi
Laure-Eve Montfort - T.: +32 (0)2 290 90 93 – **celyad@comfi.be**

For the U.S.: LifeSci Advisors
Daniel Ferry – T.: +1 (617) 535 7746 **– daniel@lifesciadvisors.com**
Public Relations: Sara Zelkovic – T:+1 (646) 876 4933 **- sara@lifescipublicrelations.com**

Forward-looking statements

This release may contain forward-looking statements, including statements regarding the safety and efficacy of CYAD-01 and CYAD-101; the ongoing and planned clinical development of CYAD-01 and CYAD-101, including the timing of trials, enrollment, data readouts and presentations; the clinical and commercial potential of CYAD-01 and CYAD-101 and the adequacy of Celyad's financial resources; Celyad's worldwide development and commercialization rights to CYAD-101; the ongoing and planned clinical and commercial potential and development of its shRNA technology; Celyad's financial condition, results of operation and business outlook; and the effects of Dr. Moore joining Celyad. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual results, financial condition and liquidity, performance or achievements of Celyad, or industry results, to differ materially from those expressed or implied by such forward-looking statements. In particular it should be noted that the data summarized above are preliminary in nature. There is limited data concerning safety and clinical activity following treatment with the CYAD-01 and CYAD-101 drug product candidates. These results may not be repeated or observed in ongoing or future studies involving the CYAD-01 and CYAD-101 drug product candidates. These forward-looking statements are further qualified by important factors and risks, which could cause actual results to differ materially from those in the forward-looking statements, including statements about: the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our ability to advance drug product candidates into, and successfully complete, clinical trials; our ability to successfully manufacture drug product for our clinical trials, including with our mAb manufacturing process and with respect to manufacturing drug product with the desired number of T cells

under our clinical trial protocols; our reliance on the success of our drug product candidates, including our dependence on the regulatory approval of CYAD-01 and CYAD-101 in the United States and Europe and subsequent commercial success of CYAD-01 and CYAD-101, both of which may never occur; the timing or likelihood of regulatory filings and approvals; our ability to develop sales and marketing capabilities; the commercialization of our drug product candidates, if approved; the pricing and reimbursement of our drug product candidates, if approved; the implementation of our business model, strategic plans for our business, drug product candidates and technology; the scope of protection we are able to establish and maintain for intellectual property rights covering our drug product candidates and technology; our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights and proprietary technology of third parties; cost associated with enforcing or defending intellectual property infringement, misappropriation or violation; product liability; and other claims; regulatory development in the United States, the European Union, and other jurisdictions; estimates of our expenses, future revenues, capital requirements and our needs for additional financing; the potential benefits of strategic collaboration agreements and our ability to maintain and enter into strategic arrangements; our ability to maintain and establish collaborations or obtain additional grant funding; the rate and degree of market acceptance of our drug product candidates, if approved; our financial performance; developments relating to our competitors and our industry, including competing therapies and statements regarding future revenue, hiring plans, expenses, capital expenditures, capital requirements and share performance. A further list and description of these risks, uncertainties and other risks can be found in Celyad's U.S. Securities and Exchange Commission (SEC) filings and reports, including in its Annual Report on Form 20-F filed with the SEC on April 6, 2018 and subsequent filings and reports by Celyad. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document and Celyad's actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.